The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prostate-specific antigen value at 3 & 7 months (PSA-3mo, PSA-7mo) and overall survival (OS) in metastatic hormone-sensitive prostate cancer (mHSPC) treated with androgen deprivation (ADT) with or without orteronel (SWOG S1216).
 
Mamta Parikh
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb; Exelixis; Natera; OncoCyte; Seagen
Research Funding - Karyopharm Therapeutics
 
Catherine Tangen
No Relationships to Disclose
 
Maha H. A. Hussain
Honoraria - Astellas Pharma; AstraZeneca; AstraZeneca; Clinical Care Options; Great Debates and Updates; Medscape; Merck; Precisca; Targeted Oncology; UroToday
Consulting or Advisory Role - AstraZeneca; Bayer; Bayer; Convergent Therapeutics; GlaxoSmithKline; GlaxoSmithKline; Janssen; Merck; Novartis; Pfizer; Tempus
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Genentech (Inst); PCCTC (Inst); Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - TITLE: Dual Inhibition of MET and VEGF for the treatment of castration resistant prostate cancer and osteoblastic bone metastases. Applicant/Proprietor Exelexis, Inc. Application No/Patent No. 11764665.4- 1464 Application No/Pat; TITLE: METHOD OF TREATING CANCER Docket No: Serial Number: 224990/10-016P2/311733 61/481/671 Application Filed on: 5/2/2011; TITLE: SYSTEMS AND METHODS FOR TISSUE IMAGING, 3676 Our File: Serial Number: UM-14437/US-1/PRO 60/923,385 UM-14437/US-2/ORD 12/101,753
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar; Nektar
Honoraria - Bristol Myers Squibb Foundation
Consulting or Advisory Role - EMD Serono; Foundation Medicine; Gilead Sciences; Guardant Health; Loxo/Lilly; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Janssen Oncology; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Yeonjung Jo
No Relationships to Disclose
 
Andrea Harzstark
No Relationships to Disclose
 
Channing Judith Paller
Consulting or Advisory Role - Dendreon; Exelixis; Omnitura
Research Funding - Lilly (Inst)
 
Saby George
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; Eisai; EMD Serono; Exelixis; Merck; Pfizer; QED Therapeutics; Sanofi; Seattle Genetics/Astellas
Research Funding - Agensys (Inst); Aravive (Inst); Aveo (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Seattle Genetics/Astellas (Inst); Surface Oncology (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb/Medarex; Sanofi
 
Matthew R. Zibelman
Honoraria - Pfizer
Consulting or Advisory Role - AVEO; Blue Earth Diagnostics; EMD Serono; Exelixis; Janssen; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Horizon Pharma (Inst)
Other Relationship - Association of Community Cancer Centers (ACCC)
 
Heather H. Cheng
Consulting or Advisory Role - AstraZeneca; AstraZeneca (I)
Research Funding - Clovis Oncology (Inst); Color Genomics Foundation (Inst); Janssen (Inst); Medivation/Astellas (Inst); Phosplatin Therapeutics (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate
Other Relationship - Janssen
 
Benjamin L. Maughan
Consulting or Advisory Role - Astellas Medivation; AVEO; Bavarian Nordic; Bayer; Bristol-Myers Squibb; Clovis Oncology; Exelixis; Janssen Oncology; Merck; Peloton Therapeutics; Pfizer; Tempus
Research Funding - Bavarian Nordic (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Exelixis (Inst)
Travel, Accommodations, Expenses - Exelixis
 
Jingsong Zhang
Honoraria - AstraZeneca/MedImmune; Bayer; Dendreon; EMD Serono; Pfizer; Sanofi; Sanofi/Aventis; Seagen
Consulting or Advisory Role - AstraZeneca/MedImmune; Bayer; Dendreon; EMD Serono; Pfizer
Speakers' Bureau - AstraZeneca; Dendreon; Sanofi; Seagen
 
Russell Kent Pachynski
Consulting or Advisory Role - Bayer; Blue Earth Diagnostics; Bristol-Myers Squibb; Dendreon; EMD Serono; Genomic Health; Jounce Therapeutics; Pfizer/EMD Serono; Sanofi
Speakers' Bureau - AstraZeneca; Dendreon; Genentech/Roche; Genomic Health; Merck; Sanofi
Research Funding - Bristol Myers Squibb Foundation (Inst); Exelixis (Inst); Janssen Oncology; Pharmacyclics (Inst)
Patents, Royalties, Other Intellectual Property - Entitled: METHOD OF CELL-FREE DNA ANALYSIS TO IDENTIFY HIGH-RISK METASTATIC PROSTATE CANCER
Travel, Accommodations, Expenses - Genentech/Roche
 
Alan Haruo Bryce
Honoraria - Advanced Accelerator Applications/Novartis; Astellas Pharma; AstraZeneca; Bayer; Castle Biosciences; Horizon CME; Myovant Sciences; Myovant Sciences; Pfizer; Research to Practice; Research to Practice; Verity Pharmaceuticals
Research Funding - Janssen Oncology (Inst)
Travel, Accommodations, Expenses - Clovis Oncology (Inst); Phosplatin Therapeutics (Inst)
 
Daniel W. Lin
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Lantheus Medical Imaging
Research Funding - GenomeDx (Inst); Magforce (Inst); MDxHealth (Inst)
 
David I. Quinn
Employment - Abbvie
Honoraria - AVEO; Bayer; Bristol-Myers Squibb; Clinigen Group; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Seagen
Consulting or Advisory Role - AVEO; Bayer; Bristol-Myers Squibb; Clinigen Group; Eisai; Exelixis; Genentech/Roche; Merck Sharp & Dohme; Myovant Sciences; Pfizer; Seagen; US Biotest
Research Funding - Genentech/Roche (Inst); Merck (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis
(OPTIONAL) Uncompensated Relationships - Eisai; US Biotest
 
Ian M Thompson
Leadership - H-E-B (grocery store chain)
Consulting or Advisory Role - Magforce
Research Funding - MagForce
Patents, Royalties, Other Intellectual Property - I have several patents with colleagues involving novel biomarkers for cancer and two devices for sexual dysfunction and urinary incontinence. No revenues at this time and our University IP office is working with industry to determine if these can be comme
 
Tanya B. Dorff
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bayer; Exelixis; Janssen Oncology; Pfizer; Sanofi/Aventis; Seagen
Research Funding - Pfizer (Inst)
 
Primo N Lara
Research Funding - Janssen Biotech (Inst); Taiho Pharmaceutical (Inst)
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; Astellas Pharma; AstraZeneca; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Foundation Medicine; Foundation Medicine; Genentech; Gilead Sciences; Janssen Oncology; Lilly; Lilly; Lilly; Medivation/Astellas; MEI Pharma; Merck; Nektar; Novartis; Pfizer; Pfizer; Pharmacyclics; Seagen
Research Funding - Amgen (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); crispr therapeutics (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); Immunomedics (Inst); Janssen (Inst); Lilly (Inst); Merck (Inst); Nektar (Inst); ORIC Pharmaceuticals (Inst); ORIC Pharmaceuticals (Inst); Pfizer (Inst); Takeda (Inst)